The effect of mitochondrial fusion on chondrogenic differentiation of cartilage progenitor/stem cells via Notch2 signal pathway

Safwat Adel Abdo Moqbel1,2,3†, Rong Zeng1,2,3†, Diana Ma1,2,3†, Langhai Xu4, Changjian Lin1,2,3, Yuzhe He1,2,3, Chiyuan Ma1,2,3, Kai Xu1,2,3, Jisheng Ran1,2,3*, Lifeng Jiang1,2,3* and Lidong Wu1,2,3*

Abstract

Background: Osteoarthritis (OA) is a debilitating disease that inflicts intractable pain, a major problem that humanity faces, especially in aging populations. Stem cells have been used in the treatment of many chronic diseases, including OA. Cartilage progenitor/stem cells (CPSCs) are a type of stem cells with the ability to self-renew and differentiate. They hold a promising future for the understanding of the progression of OA and for its treatment. Previous studies have reported the relationship between mitochondrial dynamics and mesenchymal stem cell (MSC) proliferation, differentiation and aging. Mitochondrial dynamic and morphology change during stem cell differentiation.

Methods: This study was performed to access the relationship between mitochondrial dynamics and chondrogenic differentiation of CPSCs. Mitochondrial fusion and fission levels were measured during the chondrogenic differentiation process of CPSCs. After that, we used mitochondrial fusion promoter to induce fusion in CPSCs and then the chondrogenic markers were measured. Transmission electron microscopy (TEM) and confocal microscopy were used to capture the mass and fusion status of mitochondria. Lentiviruses were used to detect the role of mitofusin 2 (Mfn2) in CPSC chondrogenic differentiation. In vivo, Mfn2 was over-expressed in sheets of rat CPSCs, which were then injected intra-articularly into the knees of rats.

Results: Mitochondrial fusion markers were upregulated during the chondrogenic induction process of CPSCs. The mass of mitochondria was higher in differentiated CPSC, and the fusion status was obvious relative to undifferentiated CPSC. Chondrogenesis of CPSCs was upregulated with the induction by mitochondrial fusion promoter. Mfn2 over-expression significantly increased chondrocyte-specific gene expression and reversed OA through NOTCH2 signal pathway.

Conclusions: Our study demonstrated that the mitochondrial fusion promotes chondrogenesis differentiation of CPSCs. Mfn2 accelerates the chondrogenesis differentiation of CPSCs through Notch2. In vivo, Mfn2-OE in sheets of rCPSCs ameliorated OA in the rat model.

Keywords: Osteoarthritis, Mitochondrial fusion, Cartilage progenitor/stem cell, Mfn2, Notch2

Introduction

Osteoarthritis (OA), the most common form of arthritis, spreads widely across aged populations and is characterized by loss of articular chondrocytes and joint failure [1]. Articular cartilage has a limited ability to self-repair, especially after trauma or degenerative disease due to its
avascular character [2]. Nowadays, the treatment of OA is limited to symptomatic treatment.

Cartilage progenitor/stem cells (CPSCs) are a promising source of cells that possess the ability to differentiate into chondrogenic, osteogenic, and adipogenic tissue. Several studies have investigated the differential ability of CPSCs in vivo and in vitro, and they were able to survive in vivo after implantation [3–5]. Progenitor cells isolated from different tissues such as bone marrow, adipose tissue and umbilical cord hold potential and prospects for cartilage repair [6]. Furthermore, the intraarticular injection of stem cells in OA mice model has been shown to reduce inflammation and has chondroprotective effects [7, 8]. Additionally, the differentiation process of progenitor cells is associated with increasing mitochondrial mass.

Mitochondria is the most dynamic responsive system in the cell [9]. Mitochondrial dynamics, including fusion and fission, play a vital role in several biological processes in stem cells and are very important for the metabolic regulation of cellular energy [10]. Several studies have demonstrated the effect of mitochondrial dynamics during somatic cell differentiation [11]. Outer membrane fusion is mediated by mitofusins, Mfn1 and Mfn2, while inner membrane fusion is controlled by Optic Atrophy 1 (Opa1) [12]. Previous studies showed that inhibiting fusion in progenitor cells leads to failure in differentiation [13]. Dynamic-related protein (DRP1) and fission-1 (Fis1) are the regulators of mitochondrial fission [14]. Inhibition of DRP1 by interfering RNA or Mdivi-1 increased cardiac differentiation of human pluripotent stem cells [15].

In light of these findings, we decided to study the mitochondrial dynamics of chondrogenic differentiation of CPSCs. We hypothesized that increasing cell mitochondrial fusion by over-expressing Mfn2, a key regulator of mitochondrial fusion, or using a chemical promoter, may promote chondrogenic differentiation of CPSCs.

Mitochondrial fusion promoter M1 was employed to detect the role of mitochondrial fusion in chondrogenic differentiation of CPSCs, and then lentiviruses were used to detect the role of Mfn2 in chondrogenic differentiation of CPSCs in vitro. A group of rats underwent medial meniscus resection and then received a sheet of rCPSCs with overexpressed Mfn2 intra-articularly.

**Methods**

**Materials and reagents**

Fetal bovine serum (FBS), streptomycin, penicillin, 0.25% pancreatic enzyme and DMEM were obtained from Gibco, USA. Chondrogenic induction medium, osteogenic induction medium and adipogenic induction medium were obtained from Cyagen US Inc. Hematoxylin and BSA were obtained from Sigma-Aldrich, USA. Mitochondrial fusion promoter M1 was obtained from Selleckchem (Shanghai, China).

**Preparation of cartilage/stem progenitor Cells (CPSCs)**

Cartilage was isolated from the knee and hip joints of twenty 3-week-old male Sprague–Dawley (SD) rats (Zhejiang Academy of Medical Science, Hangzhou China) as mentioned in [16]. In brief, the rats were euthanized with pentobarbital and then under sterile requirements the cartilages tissues were isolated. Cartilage tissues (≤1.5 g) were digested with 5 ml of 0.25% Trypsin–EDTA for 30 min. Afterward, the trypsin–EDTA solution was removed by centrifuge and then the tissues were washed with PBS. Next, the tissue samples were incubated with 6 ml DMEM containing 1 ml of 0.2% collagenase II for 4 h at 37 °C on a horizontal shaker. Subsequently, the cells were centrifuged and then suspended in DMEM containing 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. The cells were then seeded in tissue culture flasks at 37 °C with 5% CO₂ as passage 0 (P₀). When the cells in the culture flask reached a density above 80%, the cells were released into the medium with trypsin and collected

| Table 1 | Primer sequences used in this study |
| --- | --- |
| Gene | Accession number | Amplicon length (bp) | Forward | Reverse | Tm (°C) |
| Rat Col2a1 | NM_012929.1 | 151 | GCCCAGGATGCCCCGAAAATTA | CTCGTTGGAGCCACTTCT | 61.5 |
| Rat Acan | XM_039101035.1 | 196 | CTGGGTGGATGCAGAGGAC | TTGTTTTGAGCCACTTCT | 60.1 |
| Rat Sox-9 | NM_080403.2 | 170 | AACGCGGAGAACTGGGCA | GTGGTGGAAGAGGGAG | 60.11 |
| Rat Mfn2 | NM_130894.4 | 118 | TCAAGCCACGTTGAGGAG | CACAGATGACAAATG | 60.17 |
| Rat Mfn1 | NM_138976.1 | 136 | ATCTGCTGAGATACAGGGCT | TCCACAGAGATGGGAT | 60.61 |
| Rat Opal | NM_133585.3 | 108 | GGCACTTCAGCTGCTTCA | CACTGCTTTGGGTCCAGT | 60 |
| Rat Drp1 | NM_053655.3 | 94 | AGGTTTCCGAGTGACAAAGA | CACAGCACTATACAGAGT | 60.18 |
| Rat Fis1 | NM_001105919.1 | 108 | AGCCCGTTGAGCTTCTTC | GCAACCTCGCCATCTCAC | 60.67 |
| Rat 18S | NR_046237.2 | 172 | CCTGAGAAACGGCCTACACA | ACCAGAATGCCCTCCAAT | 60.96 |
to be reseeded. After passage 0, cells were seeded at very low density to form colonies (2–3 cells/cm²), and these cells were designated as CPSCs. The medium was replaced every 3 days, and after 10 days, the cell density reached over 80% in the culture flasks.

**Transduction of cells**

In order to identify if mitochondrial fusion is able to affect CPSC differentiation, we chose *Mfn2* as a representative factor. To confirm the role of *Mfn2* during chondrogenic differentiation of CPSCs, endogenous *Mfn2* was over-expressed or down-regulated by lentiviral particles. According to its effectiveness, shRNA (sense: 5′ CCAAAUUGCUAGGAAUAAATT-3′, anti-sense: 5′UUAAUGCUGAAGGAAUUGTT-3′) was chosen to down-regulate the expression of *Mfn2*. A scrambled shRNA sequence (TTCTCGAACGTTCACGT) was used as a negative control group (*Mfn2*-KD control group (KD-NC)). Lentivirus overexpression *Mfn2* (Lenti-*Mfn2*) particles and lentiviral GFP particles (lenti-control), Lentivirus- knockdown *Mfn2* particles (Lenti-KD), and knockdown control particles (ctrl-KD) were prepared by (Genechem; Shanghai; China). For infections, rCPSCs were incubated with lentiviral particles and Polybrene (5 μg/mL) in growth medium. After 24 h, the infection medium was replaced. GFP fluorescence was used to detect the transduction efficiency. The expression of *Mfn2* was measured by western blot and qRT-PCR. Lentiviral vectors were efficiently used to over-express or knock down *Mfn2* in > 80% of passage 3 (P3) rCPSCs.

**RNA Isolation and qRT-PCR assessment**

CPSCs were cultured in a 6-well plate at a density of 10 × 10⁶ cells/well. Total RNA was extracted using TRizol® Plus RNA Purification Kit (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. The ratio of the absorbance at 260 nm and 280 nm (A₂₆₀/A₂₈₀) was used to calculate and verify the quality and purity of the extracted RNA (200–300 ng/uL). After using PrimeScript RT Master Mix (Takara) to

---

**Fig. 1** Cartilage progenitor/stem cell (CPSC) identification. The surface marker and multipotency analysis were set to confirm the stem status of CPSCs. A CPSCs stained with CD29, CD44, CD45, CD90, Oct-4, nanog, and nucleostemin and were presented in a flow cytometric assay. B Osteogenic differentiation of CPSCs (Alizarin Red); bar = 200 μM. C Adipogenic differentiation of CPSCs (Oil Red); bar = 50 μM. D, E Chondrogenic differentiation of CPSCs (Safranin O and Alcian Blue); bar = 200 μM.
synthesize cDNA, qPCR was carried out on StepOnePlus Real-TimePCR system using SYBR Green qPCR SuperMix. mRNA expression was normalized using 18 s as a housekeeping gene. The complete list of primers used can be found in Table 1.

**Protein isolation and western blot**

Cells were seeded in a 6-well plate at a density of 10 × 10⁴ cells/well. After treatment, cells were washed twice with phosphate-buffered saline (PBS). RIPA Lysis Buffer containing phosphatase inhibitor and protease inhibitor was added for 30 min to extract all proteins. The extracted protein was analyzed using a BCA quantification kit. Equivalent amounts of gel were separated on 8%-12% SDS-PAGE gels and transferred to polyvinylidene fluoride (PVDF) membranes. The PVDF membrane was blocked in TBST with 10% skim milk for 1 h and then incubated overnight with primary antibodies at 4 °C. Then, the PVDF membrane was incubated with the secondary antibodies for 1 h at room temperature. Blotting was performed using primary antibodies: Col2 (1:1000) (rabbit; no. ab34712; Abcam), GAPDH (1:1000) (rabbit; no. ab70699; Abcam), SOX-9 (1:1000) (rabbit; no. ab185966Ab; Abcam), Acan (1:1000) (rabbit; no. ab36861; Abcam), Mfn2 (1:200) (mouse; no. Sc-100560; Santa Cruz) NICD (1:500) (rabbit; no. 10062-2-AP; Proteintech; Wuhan, China), HES1 (1:1000) (rabbit; no. ab36371; Abcam), Mfn2 (1:200) (rabbit; no. ab36371; Abcam), MFN1(1:500) (rabbit; no. 10062-2-AP; Proteintech), β-actin (1:200) (mouse; no. Sc-8432; Santa Cruz) NICD (1:500) (rabbit; no. ab36861; Abcam), MFN2 (1:200) (rabbit; no. ab36861; Abcam), Acan (1:1000) (rabbit; no. ab36861; Abcam), Mfn2 (1:200) (rabbit; no. ab36861; Abcam), HES1 (1:1000) (rabbit; no. ab36861; Abcam), NICD (1:500) (rabbit; no. ab36861; Abcam), SOX-9 (1:1000) (rabbit; no. ab36861; Abcam), Acan (1:1000) (rabbit; no. ab36861; Abcam), Mfn2 (1:200) (mouse; no. Sc-100560; Santa Cruz) NICD (1:500) (rabbit; no. 10062-2-AP; Proteintech; Wuhan, China), HES1 (1:1000) (rabbit; no. ab36861; Abcam), MFN1(1:500) (rabbit; no. 10062-2-AP; Proteintech), β-actin (1:200) (mouse; no. Sc-8432; Santa Cruz). Protein bands were visualized using an ECL kit and analyzed with Quantity One software. GAPDH and β-actin were used as controls in all western blot analysis.

**Safranin O and Alcian blue staining**

The cells were cultured as a cell sheet in 12 well plate or pellet. and then treated according to the study design. According to manufacturer’s protocol, 3 × 10⁵ cells were centrifuged at 200g at 20 °C for 5 min, and then the pellet was cultured with 0.5 ml chondrogenic differentiation medium. The cells were washed three times with PBS and then fixed with 4% paraformaldehyde solution. Pellets were incubated in 30% sucrose (Sigma-Aldrich, MO, USA) at room temperature for 24 h, and then serial sections (8 µm) were prepared and stained for at −20 °C. Subsequently, 0.75% Safranin O (Sigma-Aldrich) or Alcian blue solution (1% in 3% acetic acid, pH 2.5; Cyagen) was used to stain the cells for 7 min at room temperature. After washing the cells three times with PBS, the images were captured using microscope or gross camera.

**Immunofluorescence staining**

0.5% Triton X-100 was used to permeabilize the samples (pellets and knee joint sections) and then blocked with 5% BSA for 1 h. After that, the samples were incubated with primary antibodies for Col2 (1:100), Mfn2 (1:50) or Prg4 (1:50; Novus Biologicals) overnight at 4 °C. After 3 times of washing, the samples were then incubated with secondary anti-rabbit or anti-mouse antibodies (Alexa Fluor 488 or 555 Beyotime, China) for 1 h in the dark. Subsequently, the samples were counterstained with DAPI for 5 min and then washed with PBS and then visualized under fluorescence microscope.

**Mitochondrial dynamics imaging**

rCPSCs were seeded on circle microscope cover glass in a 24-well plate at a density of 2.5 × 10⁴ cells/well and then were cultured with or without chondrogenic induction medium (Chondrogenic basal medium, ITS supplement, TGF-β3, Sodium pyruvate, Ascorbate, Proline, and Dexamethasone). After 14 d of induction, the cells were incubated with Mito-Tracker Red (Beyotime, China) according to the manufacturer’s instructions. Fluorescence was captured using a Zeiss 510 Confocal microscope (Carl Zeiss, Germany).

**Transmission electron microscopy (TEM)**

Cells were seeded in a 6-well plate at a density of 10 × 10⁴ cells/well and then cultured with or without chondrogenic induction medium for 14 d. The cells were fixed with 2.5% glutaraldehyde 4 °C for 12 h. Using 2% osmium tetroxide to fix the samples for 1 h, the samples were dehydrated in an ascending series of acetone. After embedding, the samples were put in an oven to polymerize at 37 °C for 16 h and then at 60 °C for 14 h. The samples were wiped and then cut into semi-thin parts using ultramicrotome. Transmission electron microscope (Hitachi, Japan) was used to observe the cells.
Fig. 2 (See legend on previous page.)
In vivo experiment
All the animals were obtained from Zhejiang Academy of Medical Science, Hangzhou China. In strict accordance with the instructions for the use and care of laboratory animals and with the approval of IACUC, a total of 40 male S-D rats (6-weeks old; 190–240 g) were used to establish the in vivo experiment. This study contains four groups: sham (negative control) group, OA (destabilization of the medial meniscus) group, rCPSC-OE (rCPSCs with Mfn2-OE) group, and rCPSC-OE-NC (rCPSCs with negative-control of Mfn2-OE) group (10 rats/group). Briefly, pentobarbital (40 mg/kg) was used to anesthetize the rats. Under sterile conditions, the knee joints were opened and then the medial meniscus was resected to induce OA in the rats. The rats in the sham group received sham surgery where the knee joints were cut open without resection of the medial meniscus. After surgery, each rat received an injection with penicillin (20000 U/mL) and then divided randomly. The rCPSCs were isolated and cultured in cell flasks at 37 °C with 5% CO2 as mentioned above, and then rCPSC sheets were treated with Mfn2-OE or Mfn2-OE-NC and were passaged until P2. After that, the treated rCPSCs were collected and washed three times with PBS. After that, rCPSCs were prepared as cell suspensions of 1 × 10^6/100µL per leg and were administered by intrarticular injection into the rCPSC-OE and rCPSC-OE-NC rats 2 weeks after surgery, whereas the rats in the sham and OA groups received equal amounts of PBS injection. The injected rCPSCs were allogeneic cells. The rats were killed eight weeks after surgery.

Histological analysis
The rats were killed with intraperitoneal injection of (800 mg/kg) pentobarbital, and then, the knee joints were collected. The joints were first fixed in 4% paraformaldehyde and decalcified with 10% EDTA at room temperature for 2 months. The tissues were embedded in paraffin and cut into 5 µm sagittal sections. Slides of each joint for 2 months. The tissues were embedded in paraffin and then incubated with 0.1% Triton X-100 for 30 min and then stained with InSitu Cell Death Detection Kit according to the manufacturer’s instructions for 30 min at 37 °C. The nuclei were stained with DAPI, and the images were visualized using fluorescence microscope.

Immunohistochemical analysis
Paraffin-embedded knee joint sections were prepared and then blocked with 5% BSA for 1 h. After that, the sections were incubated with primary antibodies against Col2 (1:100), SOX-9 (1:100), Acan (1:100), HES1 (1:100), MFN2 (1:50), MMP-3 (1:100) (rabbit; no. ab52921; Abcam), and MMP-13 (1:50) (rabbit; N3C1; GeneTex) at 4 °C for 12 h. Subsequently, the samples were washed and then incubated with secondary antibody (Boster Biological Technology) for 2 h. Optical microscope was used to capture the images.

Statistical analysis
All the data were recorded more than 3 times, and statistical differences were analyzed using SPSS software (version 22.0; IBM, USA). All data are presented as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was used to assess the statistical difference between the groups. P less than 0.05 was considered as significant difference.

Results
Identification of CPSCs
The stem status markers such as CD29, CD44 and CD90 and the pluripotent markers such as CD73, Oct-4, nanog and nucleostemin were detected. The results showed high levels of stem cell markers CD 29, CD44, CD 90, CD73 and nucleostemin, with more than 60% expression of Oct-4 and 10% expression of nanog in the clonogenic cells, while CD45, a leukocyte marker, was at undetectable levels (Fig. 1A). The multipotency was verified by Oil Red staining showing differentiated adipocytes (Fig. 1C). Alcian blue and

Fig. 3 Mitochondrial fusion promoter M1 increased rCPSC differentiation toward chondrogenesis. Rat CPSCs were incubated with two different concentrations of MFP1 (5 and 10 μM). A The effect of MFP1 on mitochondrial fusion at mRNA level. B, C Western blot and quantitative analysis of MFP1 on mitochondrial fusion. D–F The role of MFP1 on chondrogenic and mitochondrial fusion markers at mRNA and protein levels during chondrogenic differentiation of CPSCs. G, H Safranin O and Alcian blue staining of CPSC pellet with or without MFP1. I Col2 levels detected by immunofluorescence staining. DAPI (blue), Col2 (green). Bar = 200 μM. The data are expressed as mean ± standard deviation. N = 3. *P less than 0.05 versus control group. Col2 = collagen II; MFN = mitofusin; MFP1 = mitochondrial fusion promoter M1.
Fig. 3 (See legend on previous page.)
Safranin O staining was used to show the chondrogenic differentiation ability of CPSCs (Fig. 1D, E).

**Mitochondrial fusion is up-regulated during chondrogenic differentiation of rCPSCs, while fission is down-regulated**

Because cell differentiation is a process that requires enough energy, we hypothesized that changes in mitochondrial dynamics occur during commitment to differentiation. Thus, we measured markers of mitochondrial fusion and fission during the chondrogenic differentiation process of rCPSCs. Firstly, CPSCs were induced with chondrogenic induction medium, and then the chondrogenic markers such as collagen II, aggrecan, and SOX-9 were assessed to confirm that the CPSCs differentiated successfully toward chondrogenic lineage. Mitochondrial fusion markers were then evaluated to prove that fusion markers are up-regulated during the chondrogenic process of CPSCs. The levels of Mfn2, Mfn1, and Opal significantly increased during chondrogenic differentiation of rCPSCs (Fig. 2A–C), while levels of Drp1 and Fis1 decreased during chondrogenic differentiation (Fig. 2A–C). In addition, mitochondrial mass increased during chondrogenic induction compared to normal CPSCs (Fig. 2D and Additional file 1: Fig. S1A and B). Furthermore, we observed more mitochondrial fusion in the differentiated CPSC compared to undifferentiated CPSC by TEM (Fig. 2E). Our data confirmed that mitochondrial fusion and mitochondrial mass increased in commitment to chondrogenesis relative to undifferentiated CPSCs.

**The induction of mitochondrial fusion promotes differentiation of rCPSCs toward chondrogenesis**

To confirm the relationship between mitochondrial fusion and chondrogenic differentiation of CPSCs, we used mitochondrial fusion promoter 1 (MFP1) to induce mitochondrial fusion and then measured the chondrogenic markers of CPSCs. The treatment of CPSCs with MFP1 at concentrations of 5 and 10 uM are able to up-regulate levels of chondrogenic markers such as Col2, Sox-9 and Acan. We initially used two different concentrations of MFP1 to confirm that mitochondrial fusion can be induced. The levels of Mfn2, Mfn1, and Opal were measured at protein and mRNA levels. MFP1 was able to up-regulate the levels of mitochondrial fusion (Fig. 3A–C). Next, we used chondrogenic medium to induce chondrogenic differentiation of rCPSCs with or without adding MFP1. The results showed increase of chondrogenic markers at mRNA and protein levels (Fig. 3D–F). Furthermore, we found that the levels of mitochondrial fusion markers also increased in these samples. To confirm the role of MFP1 in rCPSC chondrogenic differentiation, we used Safranin O and Alcian blue staining to detect chondrogenic phenotypes. The results showed increased Safranin O and Alcian blue staining in the MFP1-treated group (Fig. 3G, H). Additionally, immunofluorescence staining showed high levels of collagen II in the MFP1-treated group relative to the non-MFP1 group (Fig. 3I).

**Mfn2 and Prg4 were co-localized in normal articular cartilage and were decreased during OA progression**

Immunofluorescence (IF) double staining was done to determine the co-localization of Mfn2 and Prg4 in normal cartilage. Green fluorescence was conducted for Mfn2, while red fluorescence was conducted for Prg4, and the nuclei were stained with DAPI. The results showed that Mfn2 was co-localized with Prg4 in most cells especially on the surface layer of the cartilage (Fig. 4A). Furthermore, we induced OA by DMM in 30 (6-week-old) mice and then collected the limbs after 1, 6 and 8 weeks of the surgery. The results showed that Mfn2 and Prg4 gradually decreased across the different stages of OA induction (Fig. 4B).

**The transduction efficiency**

We evaluated the ratio of green fluorescent protein (GFP) positive cells to the total number to quantify the efficiency of the lentiviral vectors (Fig. 4C). Mfn2 expression was measured using qRT-PCR and western blot after 5 days of infection. mRNA and protein levels of Mfn2 were...
Fig. 4 (See legend on previous page.)
significantly up-regulated or down-regulated relative to the control groups (Fig. 4D–F).

**Mfn2-OE increases the levels of chondrogenic genes and proteins**

The levels of chondrogenic genes and proteins, including Col2, Sox-9 and Acan, were detected using qRT-PCR and western blot to measure the role of Mfn2 in differentiation of rCPSCs toward chondrogenesis. The results showed high levels of chondrogenic markers in the OE group relative to the OE-NC group (Fig. 5A, B). Furthermore, Safranin O and Alcian blue staining were used to detect glycosaminoglycan, a cartilage matrix component. The results showed that the intensity of Safranin O and Alcian blue staining increased in the OE group relative to OE-NC group (Fig. 5D–G). In addition, IF was used to detect the expression of collagen II, which increased in the OE group relative to the OE-NC group (Fig. 5H). To confirm the role of Mfn2-OE, we assessed the effects of OE relative to Mfn2-KD. The results showed higher expressions of chondrogenic markers in the OE group compare to the other groups (Additional file 2: Fig. S2A, B). No wonder, OE group has the highest intensity of Safranin O and Alcian blue staining compared to other groups (Additional file 2: Fig. S2D, E).

**Mfn2-OE reduces Notch2 signaling pathway**

To investigate the role of Mfn2 on rCPSC chondrogenic differentiation, we investigated the signaling pathways which are involved in MSC chondrogenic differentiation, such as TGF-β (Smad3, Smad4, and Smad2), β-catenin, and Notch (Notch1, Notch2, and Notch3) as shown in Fig. 9. Firstly, we used chondrogenic medium to induce chondrogenesis in CPSCs at different time points. Then, western blot was run to assess the involvement of the above-mentioned signaling pathways. The results showed high levels of TGF-β signaling along with increased induction time of chondrogenic medium, while β-catenin and Notch signaling reduced (Fig. 6A, B). After that, we infected the cells with Mfn2 lentiviral vectors and measured the protein levels of those signaling pathways. Interestingly, NOTCH2, NICD and HES1 were down-regulated in the OE-group (Fig. 6C, F).

**rCPSC sheets with over-expression Mfn2 ameliorates OA in vivo**

To further investigate in vitro outcomes, sheets of rCPSCs with Mfn2-OE were used in rat OA model induced by DMM surgery. After the cells were infected with Mfn2 lent-OE and its negative control, they were injected into the knee joints of rats. In this experiment, transduced cells with OE-NC were used rather than non-transduced cells due to the comparison results between OE-NC and blank group in vitro study. The results showed no significant difference between blank group and OE-NC group (Additional file 3: Fig. S3). Thus, we chose OE-NC as a control group for OE and OA. In addition, the control group of OE (OE-NC) has no nucleotide sequence. At eight weeks post-surgery, the histological analysis was conducted. Safranin O, hematoxylin–eosin (HE), TUNEL and immunohistochemical staining were performed. According to the Safranin O staining results, cartilage degeneration was significantly ameliorated by treatment with rCPSCs sheets compared with the OA group. Furthermore, a larger improvement was found in the OE group than in the OE-NC group (Fig. 8A). Mankin and OARSI were conducted to confirm the role of OE (Fig. 7D, E). Safranin O staining showed inhibition of synovial hyperplasia in the OE-NC group compared to the OA group, as well as greater suppression of cartilage destruction in the OE than in the OE-NC group. These results were supported by HE staining (Fig. 7B). TUNEL staining showed that the injection of rCPSCs alleviated the destructive changes and apoptosis in the cartilage matrix (Fig. 7C). Additionally, immunohistochemical study revealed that expression of chondrocyte specific markers, such as Col2, SOX-9, and Acan, increased in the OE-NC group compared to the OA group. A greater increase in the levels of these chondrocyte specific markers were observed in the OE group (Fig. 8A–C). MFN2 expression was higher in OE-group, while HES1 showed high level expression in OA group (Fig. 8D, E). OA progression markers, MMP-3 and MMP-13, were significantly reduced by the injection of rCPSCs, and lower expression levels were observed in the OE-group (Fig. 8F, G). Taken together, these results revealed that the injection of CPSCs is able to alleviate OA and showed even more promising results with over-expressed Mfn2 cells.
Fig. 5 (See legend on previous page.)
Discussion
Most tissues and organs in the body have some progenitor/stem cells in a quiescent state. Their ability to self-renew and differentiate allows these cells to produce new functional cells in order to maintain the homeostasis of tissues and organs. Cartilage tissue contains a special kind of progenitor/stem cells called cartilage progenitor/stem cells (CPSCs). CD29, CD90 are highly
expressed in these multipotent, colony forming cells [17]. Progenitor/ stem cells produce different types of cells in a process that requires vast functional re-arrangements. Mitochondria supplement ATP which is essential for differentiation and therefore play an important role in stem cell differentiation. Previous research have reported that the shape of mitochondria changes depending on physiological states of the cell [18]. In addition, mitochondrial dynamics fission/fusion is important for MSCs differentiation, and the regulation of the dynamics can promote the differentiation process [14, 19]. However, the mechanisms by which mitochondria participate in the differentiation of CPSCs remain unclear (Fig. 9).

In the present study, we uncovered the role of mitochondrial fusion in chondrogenic differentiation of CPSCs, where promoting mitochondrial fusion leads to chondrogenic differentiation of CPSCs.

Previous studies reported that mitochondrial chemical promoter (MFP1) is able to increase levels of MFN1 and 2 [20]. After confirming the ability of MFP1 to up-regulate mitochondrial fusion, we assessed the levels of collagen II, aggrecan, and SOX-9, and found that MFP1 is able to increase chondrogenesis of CPSCS (Fig. 3). Altogether, our data demonstrate the relationship between mitochondrial fusion and chondrogenic differentiation of CPSCs, which suggest that mitochondrial fusion is able to govern differentiation of CPSCs toward chondrogenic lineage.

Mitochondrial outer and inner membrane fusion is regulated by mitofusin 1 and 2 (Mfn1 and Mfn2) and optic atrophy1 (Opa1), respectively [21]. Knock-down of Mfn1 and Mfn2 resulted in fragmentation of mitochondria [22]. The fragmentation of mitochondria may indicate that a degradation process is occurring for these organelles, which is attributed to increased mitochondrial fission [14]. According to previous literature, earlier events of the chondrogenesis of MSCs could involve a fragmented phenotype of mitochondria with increasing in mitochondrial fission [19]. However, last mentioned literature showed that the expression of Mfn2 has no significant difference between control group and chondrogenic group in the early stage of chondrogenesis, while the fission markers were increased. Our results showed that the expression of mitochondrial fusion markers increased according to the prolonged chondrogenic induction time (3, 7, 14 d). In contrast, the fission markers were decreased. Furthermore, the ETM and confocal microscopy results approved the fusion status and increasing mitochondrial mass during the chondrogenesis of CPSCs. In summary, mitochondrial fragmentation has not been observed during the chondrogenesis of CPSC due to the detection time of chondrogenesis or CPSCs and MSCs may have different performance in mitochondrial dynamic during the chondrogenic process.

Not surprisingly, loss of Mfn2 leads to skeletal muscle atrophy and severe defects in placental trophoblastic giant cells [23]. Ablation of mitochondrial fusion proteins impairs the ability of embryonic stem cells to differentiate into cardiomyocytes [13]. Due to its vital role in mitochondrial fusion, we selected Mfn2 to investigate the role of mitochondrial fusion in CPSC chondrogenic differentiation. The Prg4 expressing cells are mostly located on the surface and serve as progenitor cells for the deeper layers of the cartilage [24]. Thus, we evaluated the co-localization of Mfn2 and Prg4 in normal cartilage. The results showed that Mfn2 and Prg4 were co-localized in the normal cartilage (Fig. 3A). Furthermore, Mfn2 and Prg4 gradually decreased with extended OA induction time (Fig. 3B). From these results, we deduce that Mfn2 may play a role in CPSC differentiation. Subsequently, we found that endogenous expression of Mfn2 was up-regulated in rCPSCs during chondrogenesis. Therefore, we used Mfn2-OE or KD to promote or inhibit chondrogenesis of CPSCs and found that Mfn2-OE promoted chondrogenesis of rCPSCs (Fig. 5 and Additional file 2: Fig. S2).

Extensive studies have demonstrated that various signaling pathways are involved in regulating the differentiation process of progenitor cells, including Wnt, Hedgehog, Notch, and TGF-β [25]. Notch signaling pathway plays an essential role in skeletal development. Several studies have reported that Notch activation leads to suppression of chondrogenic differentiation, and over-expression of Notch1 and Notch2 in stem cells inhibit expression of chondrogenic factors [26–28]. Furthermore, the activation of Notch signaling pathway may interact with mitochondria [29]. Among these proteins, the results showed that Mfn2-OE is able to down-regulate Notch2 signaling pathway (Fig. 6).

OA, is a chronic joint disease characterized by degenerative changes of the cartilage manifested as pain and limited activity of the joint. It is of great clinical significance.
Fig. 7 (See legend on previous page.)
to explore the molecular and cytological mechanisms of OA pathogenesis, in order to find new targets for prevention and treatment of OA. Various studies have reported the relationship between OA and mitochondrial dysfunction [30, 31]. It has been reported that the Notch pathway is remarkably up-regulated during OA development [32].

To further investigate the findings in vitro, rCPSC sheets with Mfn2-OE or OE-NC were injected intra-articularly in the rat OA model. The cartilage was assessed in the animal experiment, and erosion and loss of cartilage matrix was observed in the OA group. The cartilage damage was ameliorated by the injection of CPSCs with Mfn2-OE negative control and more improvement was observed in the OE group (Fig. 7). Immunohistochemistry staining showed that levels of chondrogenic markers, such as Col2, SOX-9 and Acan, increased in the OE-NC group and even more so in the OE group compared to the OA group (Fig. 8). Furthermore, Mfn2-OE ameliorated OA according to the OARSI and Mankin score, and reduced extracellular matrix destruction.

**Fig. 8** A sheet of rCPSCs with Mfn2 over-expression increased cartilage specific proteins and decreased cartilage damage proteins in a rat OA model. **A–G** Immunohistochemistry staining for antibodies against Col2, SOX-9, Acan, MFN2, HES1, MMP-3 and MMP-13. Bar = 200 µM. **H–N** Quantitative analysis of positive cells. OA = osteoarthritis, MMP = matrix metalloproteinase
markers, such as MMP-3 and MMP-13 according to immunohistochemistry staining (Figs. 7 and 8).

**Conclusion**

The present study corroborates the role of mitochondrial fusion in chondrogenic differentiation of CPSCs via regulating the *Notch2* signal pathway. All of the findings of the in vitro experiments were taken seriously and applied in vivo. Our findings suggest that mitochondrial fusion accelerates chondrogenic differentiation of CPSCs and holds therapeutic potential for the treatment of OA.

**Abbreviations**

MSCs: Mesenchymal stem cells; rCPSC: Rat cartilage progenitor/stem cells; OA: Osteoarthritis; TEM: Transmission electron microscopy; Mfn2: Mitofusin 2; DRP1: Dynamic-related protein; Mfn1: Mitofusin 1; Fis1: Fission; Acan: Aggrecan; FBS: Fetal bovine serum; MMP: Matrix metalloproteinase; DMEM: Dulbecco’s modified eagle medium; qRT-PCR: Quantitative RT-PCR; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; PBS: Phosphate-buffered saline; NC: Negative control; OE: Overexpress; DMM: Destabilization of the medial meniscus; Opa1: Optic atrophy1; IF: Immunofluorescence; HE: Hematoxylin–eosin; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling; TGF-β: Transforming growth factor-β.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13287-022-02758-7.

**Additional file 1: Fig. S1.** Mito-Tracker Red images of differentiated and undifferentiated CPSCs. A CPSCs were seeded in 24-well plate and then incubated with or without chondrogenic medium for 14 d. The images were captured with immunofluorescence microscopy. Mito-Tracker Red (Red), DAPI (blue). B The quantitative analysis.

**Additional file 2: Fig. S2.** The effect of MFN2 OE and KD on CPSC chondrogenic differentiation. A Relative mRNA expression of chondrogenic genes (Sox-9, Col2, and Acan) at day 14 of chondrogenesis. B, C The expression of chondrogenic proteins (SOX-9, Col2, and Acan) at day 14 of chondrogenesis, and quantitative analysis. D, E Safranin O and Alcian blue staining of chondrogenic differentiation in plate culture with chondrogenic medium for 21 days. Bar = 200 µM. The data are expressed as mean ± standard deviation, N = 3. *P less than 0.05 versus OE-NC, KD or KD-NC. OE over-expression of Mfn2, OE-NC negative control group of Mfn2 over-expression, KD knockdown of Mfn2, KD-NC negative control of Mfn2 knockdown.

**Additional file 3: Fig. S3.** The comparison between blank group and OE-NC group. A Cell counting Kit-8 was used to compare between the two groups at 24 h and 48 h. B The expression of chondrogenic markers of CPSCs at mRNA level using qRT-PCR. C Western blot was used to evaluate the chondrogenic markers of CPSCs at protein level. The data are expressed as mean ± standard deviation, N = 3. *P less than 0.05 versus OE-NC. OE-NC negative control group of Mfn2 over-expression.

**Fig. 9** Schematic illustration of the proposed mechanisms for chondrogenic differentiation of CPSCs and the interaction of mitochondrial fusion with NOTCH2 signaling pathway.
Moqbel et al. Stem Cell Research & Therapy (2022) 13:127

Acknowledgements
We are very thankful to all the clients from Orthopedic Research Institute of Zhejiang University and Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province.

Authors’ contributions
LJ, LX and LW designed the study; SAAM, RZ, DM and JR performed the study and wrote the paper; CL, YH, CM and KX analyzed the data and made the figures and tables. All authors read and approved the final manuscript.

Funding
This study was funded by the National Nature Science Foundation of China (no. 81871793, 82001458 and 81572173) and the National Science Foundation of Zhejiang Province (LD19H060001).

Availability of data and materials
The data in this study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The animal experiments were approved by The Ethics Committee of The Second Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, China).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China. 2Orthopedic Research Institute of Zhejiang University, Hangzhou, Zhejiang Province, People’s Republic of China. 3Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, Zhejiang Province, People’s Republic of China. 4Department of Pain, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, People’s Republic of China.

Received: 15 July 2021 Accepted: 24 December 2021 Published online: 25 March 2022

References
1. Kraus VB, et al. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthr Cartil. 2015;23(8):1233–41.
2. Redman S, Oldfield S, Archer C. Current strategies for articular cartilage repair. Eur Cell Mater. 2005;9(23–32):23–32.
3. Thornemo M, et al. Clonal populations of chondrocytes with progenitor properties identified within human articular cartilage. Cells Tissues Organs. 2005;180(3):141–50.
4. Dowthwaite GP, et al. The surface of articular cartilage contains a progenitor cell population. J Cell Sci. 2004;117(6):889–97.
5. Marcus P, et al. Articular chondroprogenitor cells maintain chondrogenic potential but fail to form a functional matrix when implanted into muscles of SCID mice. Cartilage. 2014;5(4):231–40.
6. Richardson SM, et al. Mesenchymal stem cells in regenerative medicine: focus on articular cartilage and intervertebral disc regeneration. Methods. 2016;99:69–80.
7. ter Huurne M, et al. Antiinflammatory and chondroprotective effects of intraarticular injection of adipose-derived stem cells in experimental osteoarthritis. Arthritis Rheum. 2012;64(11):3604–13.
8. Shen W, et al. Intra-articular injection of human meniscus stem/progenitor cells promotes meniscus regeneration and ameliorates osteoarthritis through stromal cell-derived factor-1/CXCR4-mediated homing. Stem Cells Transl Med. 2014;3(3):387–94.
9. Li Q, et al. The role of mitochondria in osteogenic, adipogenic and chondrogenic differentiation of mesenchymal stem cells. Protein Cell. 2017;8(6):439–45.
10. Horbay R, Bilyy R. Mitochondrial dynamics during cell cycling. Apoptosis. 2016;21(12):1327–35.
11. Deng H, et al. Mitochondrial dynamics regulates Drosophila intestinal stem cell differentiation. Cell Death Discov. 2018;4(1):1–13.
12. Whitley B, Engelhart E, Hopkins S. Mitochondrial dynamics and their potential as a therapeutic target. Mitochondrion. 2019;49:269–83.
13. Kasahara A, et al. Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and Notch signaling. Science. 2013;342(6159):734–7.
14. Ren L, et al. Mitochondrial Dynamics: Fission and fusion in fate determination of mesenchymal stem cells. Front Cell Dev Biol. 2020. https://doi.org/10.3389/fcell.2020.580070.
15. Hoque A, et al. Mitochondrial fusion-fission protein Drp1 inhibition promotes cardiac mesodermal differentiation of human pluripotent stem cells. Cell Death Discov. 2018;4(1):1–13.
16. Moqbel SAA, et al. Rat chondrocyte inflammation and osteoarthritis are ameliorated by Madecassoside. Oxid Med Cell Longevity. 2020. https://doi.org/10.1155/2020/7540197.
17. Jiang Y, et al. Human cartilage-derived progenitor cells from committed chondrocytes for efficient cartilage repair and regeneration. Stem Cells Transl Med. 2016;5(6):733–44.
18. Mandard S, et al. Mitochondrial function controls proliferation and early differentiation potential of embryonic stem cells. Stem Cells. 2011;29(3):486–95.
19. Fomi MF, et al. Murine mesenchymal stem cell commitment to differentiation is regulated by mitochondrial dynamics. Stem Cells. 2016;34(3):743–55.
20. Dong L, et al. Promotion of mitochondrial fusion protects against developmental PBDE-47 neurotoxicity by restoring mitochondrial homeostasis and suppressing excessive apoptotic thermogenesis. Theranostics. 2020;10(3):12145.
21. Chen H, Chan DC. Emerging functions of mammalian mitochondrial fusion and fission. Hum Mol Genet. 2005;14(suppl_2):R283–9.
22. Chen H, et al. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol. 2003;160(2):189–200.
23. Kasahara A, Scorrano L. Mitochondria: from cell death executors to developmental PBDE-47 neurotoxicity by restoring mitochondrial homeostasis and suppressing excessive apoptotic thermogenesis. Theranostics. 2020;10(3):12145.
24. Kozhemyakina E, et al. Identification of a Prg4-expressing articular cartilage progenitor cell population in mice. Arthritis Rheumatol. 2015;67(5):1261–73.
25. Chen Q, et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ. 2016;23(7):1128–39.
26. Atsumi T, et al. A chondrogenic cell line derived from a differentiating culture of AT805 teratocarcinoma cells. Cell Differ Dev. 1990;30(2):109–16.
27. Bi W, et al. Sox9 is required for cartilage formation. Nat Genet. 1999;22(1):85–9.
28. Chen S, et al. Notch gain of function inhibits chondrocyte differentiation via Rbpj-dependent suppression of Sox9. J Bone Miner Res. 2013;28(3):649–59.
29. Perumalsamy LR, Nagala M, Sarin A. Notch-activated signaling cascade interacts with mitochondrial remodeling proteins to regulate cell survival. Proc Natl Acad Sci. 2010;107(15):6882–7.
30. Mao X, et al. Mitochondria: potential targets for osteoarthritis. Front Med. 2020. https://doi.org/10.3389/fmed.2020.581402.
31. Rego-Pérez I, et al. Mitochondrial genetics and epigenetics in osteoarthritis. Front Genet. 2020;10:1335.
32. Hosaka Y, et al. Notch signaling in chondrocytes modulates endothelial ossification and osteoarthritis development. Proc Natl Acad Sci. 2013;110(5):1875–80.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.